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High mobility group box-1Abstract Introduction: In recent years, the role of high mobility group box-(HMGB-1) protein
and its receptors has received increasing attention. It has been documented that HMGB-1 is asso-
ciated with disease activity in systemic lupus erythematosus (SLE). HMGB-1 supports the inﬂam-
matory clearance of apoptotic cells and remnants. It binds to molecules released from apoptotic
cells such as nucleosomes and DNA thereby, increasing the immunogenicity of macrophages
through receptors for advanced glycation end products (sRAGE).
Aim of the work: Was to measure the plasma level of sRAGE in SLE patients and to correlate it
with the clinical and laboratory parameters of disease activity.
Patients and methods: The study was composed of 35 SLE patients; 31 females and 4 males (Group
I) and 20 age and gender matched healthy subjects as a control (Group II). All patients fulﬁlling the
American College of Rheumatology (ACR) classiﬁcation criteria for the diagnosis of SLE. Active
disease was identiﬁed using SLE disease activity index (SLE-DAI).
Demographic data, cutaneous manifestations, arthritis, vasculitis, myositis, renal, and hema-
tological disorders were recorded. In addition; complete blood picture, blood urea, seruml.: +20
(E.A.G.
152 A.N. Abou-Raya et al.creatinine, 24 h urine proteins, creatinine clearance, protein/creatinine ratio, C3, C4, Anti-nuclear
antibody, Anti-double stranded DNA were conducted for all patients and controls.
Results: The mean value of plasma level of (sRAGE) in SLE patients was signiﬁcantly higher in
SLE patients than in the normal healthy controls (P< 0.001). There was a statistically signiﬁcant
positive correlation between sRAGE and SLE-DAI (P< 0.001).
Conclusion: The plasma level of sRAGE is considered as a potential biomarker for disease activity
in SLE, severity and prognosis.
ª 2015 The Authors. Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune
disease characterized by the involvement of multiple organ sys-
tems. Its etiology is largely unknown; however, it has been pro-
posed that genetic and environmental factors contribute to
breaking tolerance, resulting in the production of a variety
of antibodies directed at self-components.1
These autoantibodies form immune complexes can be
deposited in many tissues, particularly the skin and kidneys.2,3
Currently, research is being conducted to determine what
patho-physiological mechanisms are involved in this entire
process.
Receptor for advanced glycation end products (RAGE) is a
multi-ligand member of the immunoglobulin super-family. It is
expressed by most types of immune cells, including macro-
phages, neutrophils, and T cells and interacts with several
classes of ligands.4 Currently, the known RAGE ligands
include the high mobility group box-1 (HMGB1) protein,
advanced glycation end products (AGEs), and members of
the S100/calgranulin family.5
One of the proinﬂammatory mediators is the HMGB1. It
was originally recognized as a DNAbinding protein but has
recently been identiﬁed as a damage-associated molecular pat-
tern (DAMP) molecule.6,7 This nuclear protein participates in
chromatin architecture and transcriptional regulation,8 but
once released, it induces an inﬂammatory response.9,10
Extracellular HMGB1 binds to cell surface receptors, includ-
ing RAGE, toll-like receptors 2 and 4, and others. Studies have
shown that interaction between HMGB1 and RAGE results in
the production of type -1 interferon, which plays a key role in
the pathogenesis of SLE.11,12 In addition, tumor necrosis
factor-alpha (TNF-a) and interleukin-6 (IL-6) are produced
upon HMGB-1 activation of macrophages.13
It has also been hypothesized that these cytokines also
affect some body organs as well as disease ﬂareups.14,15 In
addition, it has also been postulated that RAGE involvement
in all pathophysiological processes is reliant on HMGB1.16
Some studies have reported a relationship between the high
serum level of HMGB1 and ﬂare-ups of lupus disease activ-
ity.17,18 All of these observations support the notion that the
HMBG1–RAGE pathway plays a part in the pathogenesis of
SLE.
Another class of ligands is the AGEs. They result from a
process in which non-enzymatic glycosylation attaches to cir-
culating compounds such as lipids, proteins, or nucleic acids.
This process occurs under the effect of oxidative stress (OS)
and hyperglycemia.19 Accumulations of AGEs have beenfound in certain diseases, including diabetes mellitus (DM)
and Alzheimer’s. Since RAGE induction is under the effect
of AGEs, the RAGE-AGEs pathway is thought to be incrim-
inated in the pathogenesis of these diseases.20,21
Receptor for advanced glycation end products is a receptor
for a family of about 20 related calcium binding proteins that
are only expressed in vertebrates. These include the S100s,
which are proteins that alter several intracellular functions.22
In addition, many types of body cells release S100s during
inﬂammation; therefore, they can be used as a measure of
disease activity.23,24
Soluble RAGE (sRAGE), a truncated form of the receptor,
has the same structure but lacks the cytosolic and transmem-
brane domains. Two general mechanisms are usually responsi-
ble for the generation of soluble receptors. These are either
derived from the alternative splicing of messenger ribonucleic
acid (mRNA) or the cleaved products of the membrane-
bound form of metalloproteinase.25,26 Both sRAGE and
complete RAGE have the same ligand-binding speciﬁcity.
Furthermore, sRAGE may act as a trap for pro-inﬂammatory
ligands such as HMGB1 and inhibit their interaction with the
RAGE cell surface.27,282. Aim of the work
Was to measure the plasma level of sRAGE in SLE patients
and to correlate it with the clinical and laboratory parameters
of disease activity.
3. Patients and methods
The study was composed of 35 patients with SLE 31 females
and 4 males (Group I) and 20 age and gender matched healthy
subjects (Group II).
All of the patients conformed to the American College of
Rheumatology (ACR) classiﬁcation criteria for the diagnosis
of SLE.29 Active disease was identiﬁed using the systemic lupus
erythematosus Disease Activity Index (SLE-DAI).30
Demographic and clinical data, including cutaneous mani-
festations, arthritis, vasculitis, myositis, renal disorders were
recorded. In addition; complete blood picture,31 blood urea
nitrogen, serum creatinine, 24 h urine proteins, protein/crea-
tinine ratio, creatinine clearance,32 C3, C4,
33 anti-nuclear anti-
body, (ANA),34, and anti-double stranded DNA (Anti-ds
DNA)35 were conducted for all patients and controls.
Plasma concentrations of sRAGE levels were measured
using enzyme Linked Immunosorbant Assay (ELISA).
Table 1 Comparison between the two studied groups according to demographic data.
Cases (n= 35) Control (n= 20) Test of sig P
No. % No. %
Sex
Male 4 11.4 2 10.0 v2 = 0.027 FEP = 1.000
Female 31 88.6 18 90.0
Age
Min–max 18.0–52.0 18.0–42.0 t= 0.277 P= 0.783
Mean ± SD 33.60 ± 11.53 33.60 ± 9.52
Median 31.0 30.50
Disease duration (years)
Min–max 3.0–10.0 – – –
Mean ± SD 6.43 ± 2.08 –
Median 7.0 –
P: p value for comparing between cases and control groups.
v2 = value of Chi square.
FE: Fisher Exact test.
t= Student-test.
Table 2 The clinical description and frequency of organ
affection among the studied group.
Cases (n= 35)
No %
Arthritis 27 77.1
Fever & malaise 14 40.0
Myositis 13 37.1
Pleurisy 12 34.3
Oral ulcers 9 25.7
Photosensitivity 6 17.1
Malar rash 5 14.3
Psychosis 4 11.4
Pericarditis 4 11.4
Hair fall 2 5.7
Seizures 1 2.9
Min–max 1.0–35.0
Mean ± SD 13.83 ± 7.61
Median 15.0
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from the study, and also patients with diabetes, endocrinal
diseases, and HCV positive patients.
Written consent was taken from all patients included in the
study.
3.1. Statistical analysis of the data
Data were processed and analyzed using a computer based
program (SPSS software version 10). The results were
expressed as mean ± standard deviation (SD), and
comparisons between the SLE patients and the controls were
analyzed by the student’s t-test, one way analysis of variance
(ANOVA), and spearman’s rank correlation coefﬁcient. A
two tailed P-value of <0.05 was considered to be statistically
signiﬁcant.4. Results
Table 1: describes the distribution of the studied cases; 31 cases
(88.6%) were females and 4 cases (11.4%) were males. Their
age ranged from 18.0 to 52.0 with a mean of 33.60 ± 11.53.
The disease duration ranged from 3.0 to 10.0 with a mean of
6.43 ± 2.08. Table 2: describes the distribution and frequency
of organ involvement in SLE cases; 27 cases (77.1%) presented
with arthritis, 14 cases (40.0%) presented with fever and
malaise, 13 cases (37.1%) cases presented with myositis, 12
cases (34.3%) presented with pleurisy, 9 cases (25.7%) pre-
sented with oral ulcer, 6 cases (17.1%) presented with photo-
sensitivity, 5 cases (14.3%) presented with malar rash, 4
cases (11.4%) presented with psychosis, 4 cases (11.4%) pre-
sented with pleurisy, 2 cases (5.7%) presented with hair fall,
and 1 case (2.9%) presented with seizures. Table 3: describes
the laboratory markers of the studied SLE cases; Hb % ranged
from 8.0 to 10.50 with a mean of 9.41 ± 1.69, WBCs ranged
from 2.40 to 3.51 with a mean of 3.37 ± 2.18, platelet count
ranged from 80.0 to 130.0 with a mean of 117.46 ± 64.93,
blood urea ranged from 60.0 to 458.0 with a mean of
64.70 ± 7.66, serum creatinine ranged from 2.32 to 8.20 with
a mean of 2.50 ± 2.84, creatinine clearance ranged from 95.0
to 130.0 with a mean of 104.30 ± 8.94 and 24-h urine crea-
tinine ranged from 40.0 to 4000.0 with a mean of
1637.43 ± 1587.86. Table 4: shows the immunological markers
among the studied SLE cases; ANA ranged from 160.0 to
450.0 with a mean of 249.83 ± 230.57, anti-ds-DNA ranged
from 250.0 to 600.0 with a mean of 355.17 ± 257.15, C3 level
ranged from 95.0 to 160.0 with a mean of 147.70 ± 17.44, and
C4 level ranged from 84 to 160 with a mean of 64.57 ± 48.03.
Table 5: shows the distribution of the studied SLE cases
according to SLE-DAI Scores; 4 cases (11.4%) were with mild
SLE-DAI, 5 cases (14.3%) were with moderate SLE-DAI, and
26 cases (74.3%) were with severe SLE-DAI. Table 6: shows
comparison between the two studied groups according to
sRAGE; in SLE sRAGE ranged from 1124.0 to 1413.0 with
a mean of 1253.54 ± 66.74, while in the control group ranged
from 824.0 to 1118.0 with a mean of 975 ± 25.01. Table 7:
Table 3 Comparison between the two studied groups according to laboratory markers.
Cases (n= 35) Control (n= 20) t P
HB (gm/dl)
Min–max 8.0–13.50 11.0–15.0 4.867* <0.001*
Mean ± SD 10.41 ± 1.69 12.23 ± 1.07
Median 9.50 12.0
WBCs (·103 cell/mm3)
Min–max 2.40–9.51 4.0–9.51 0.788 0.434
Mean ± SD 5.37 ± 2.18 5.83 ± 1.87
Median 4.70 4.95
Platelets (·103 cell mm3)
Min–max 90.0–330.0 150.0–330.0 0.406 0.686
Mean ± SD 217.46 ± 64.93 224.45 ± 54.65
Median 220.0 220.0
Serum Creatinine (mg/dl)
Min–max 0.32–8.20 0.32–1.30 1.695 0.090
Mean ± SD 2.50 ± 2.84 0.89 ± 0.24
Median 0.90 0.85
Blood urea (mg/dl)
Min–max 20.0–458.0 20.0–178.0 2.090* 0.037*
Mean ± SD 34.70 ± 7.66 67.08 ± 2.84
Median 37.0 40.0
Creatinine (ml/min) clearance
Min–max 95.0 ± 130.0 7.2 ± 110.0 5.106* <0.001*
Mean ± SD 104.30 ± 8.94 56.17 ± 36.23
Median 102.0 54.30
24 h urine protein: (mg/24 h)
Min–max 40.0–4000.0 10.0–150.0 5.114* <0.001*
Mean ± SD 1637.43 ± 1587.86 61.75 ± 45.86
Median 1000.0 40.0
t= Student t-test for comparing between cases and control groups.
P: p value for comparing between cases and control groups.
* Statistically signiﬁcant at p 6 0.05.
Table 4 Comparison between the two studied groups according to immunological markers. (ANA, Anti-ds DNA, C3, C4).
Cases (n= 35) Control (n= 20) Z P
ANA (N< 1/40 IU/L)
Min–max 160.0–450.0 5.0–30.0 3.923* <0.001*
Mean ± SD 249.83 ± 230.57 15.66 ± 5.76
Median 100.0 15.0
Anti-ds DNA (N 6 30 IU/L)
Min–max 250.0–600.0 5.0–20.0 4.853* <0.001*
Mean ± SD 355.17 ± 257.15 22.50 ± 12.30
Median 380.0 20.0
C3(N 75–135 mg/dl)
Min–max 85.0–160.0 75.0–120.0 6.127* <0.001*
Mean ± SD 147.70 ± 17.44 53.49 ± 14.55
Median 150.0 50.0
C4 (N12–75 mg/dl)
Min–max 84–160 5.0–40.0 5.140* <0.001*
Mean ± SD 64.57 ± 48.03 18.05 ± 8.15
Median 61.50 16.0
Z: Z for Mann Whitney test for comparing between cases and control groups.
* Statistically signiﬁcant at p 6 0.05.
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Table 5 Distribution of the studied SLE cases according to
SLE-DAI scores.
SLE-DAI No. %
Inactive 0 0.0
Mild 4 11.4
Moderate 5 14.3
Severe 26 73.3
Min–max 5.0–35.0
Mean ± SD 17.83 ± 7.61
Median 18.0
Table 7 Correlation between sRAGE and frequency of organ
involvement among the studied group.
sRAGE
r P
Arthritis 0.608* <0.001
Fever & malaise 0.602* <0.001
Myositis 0.904* <0.001
Pleurisy 0.605 0.005
Oral ulcers 0.456 0.039
Photosensitivity 0.570 0.009
Malar rash 0.532 0.015
Psychosis 0.533 0.016
Pericarditis 0.624* <0.001
Hair fall 0.609 0.004
Seizures 0.614* <0.001
Table 8 Correlation between sRAGE and C3, C4, ANA Anti-
ds DNA, SLE-DAI, 24-h urine proteins, and protein/creatinine
ratio.
sRAGE
r P
C3 0.035 0.843
C4 0.132 0.451
ANA 0.231 0.383
Anti-ds-DNA 0.241 0.163
SLE-DAI 0.947* <0.001*
24 h-urine proteins 0.545* <0.001*
Protein/creatinine ratio 0.575 * <0.001*
r: Pearson coefﬁcient.
* Statistically signiﬁcant at p 6 0.05.
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involvement among the studied group; there was a positive
correlation between sRAGE and the presence of arthritis
(r= 0.608*, P< 0.001), fever and malaise (r= 0.602*,
P< 0.001), pericarditis (r= 0.624*, P< 0.001), hair fall
(r= 0.904*, P< 0.001), and seizures (r= 0.624*,
P< 0.001). Table 8: shows correlation between sRAGE and
C3, C4, ANA Anti-ds DNA, SLE-DAI, 24-h urine proteins,
and protein/creatinine ratio; there was a positive correlation
between sRAGE and SLE-DAI (r= 0.947*, P< 0.001),
24-h urine proteins (r= 0.545*, P< 0.001), and protein/
creatinine ratio (r= 0.575*, P< 0.001).
5. Discussion
Systemic lupus erythematosus (SLE) is a chronic, multifaceted
inﬂammatory disease that can affect every organ system of the
body. SLE is variable in its manifestations and follows a
relapsing and remitting course.36 HMGB-1 seems to be an
important molecule in the pathophysiology of SLE by sup-
porting the inﬂammatory clearance of apoptotic cells by bind-
ing to molecules released from apoptotic cells such as
nucleosomes and DNA thereby increasing the immunogenicity
of macrophages through receptors for advanced glycation end
products (RAGE) to initiate cell signaling, this uptake accom-
panied by inﬂammation.37,38
The advanced glycation end products may bind to cell sur-
face receptors to initiate cell signaling. The advanced glycation
end products receptor includes R1, wR2, R3, scavenger recep-
tors SCR-2, CD-36, and RAGE.39
As plasma sRAGE levels increased in patients with SLE,
this suggests that sRAGE may play a different role in the ini-
tial and progressive stages of the disease. However, the use of
anti-lupus therapy could be involved in the triggering of a
compensating mechanism that alters sRAGE production
and/or regulation.
In our study, the plasma level of sRAGE in SLE studied
group of patients, ranged from 1124.0 to 1412.0 with a meanTable 6 Comparison between the two studied groups according to
Cases (n= 35) Con
sRAGE (ng/dl)
Min–max 1124.0–1412.0 824
Mean ± SD 1253.54 ± 66.74 975
Median 1250.0 117of 1253 ± 66.74 while, in the control group sRAGE ranged
from 824.0 to 1118.0 with a mean of 975.30 ± 25.01. There
was a statistically signiﬁcant difference between SLE patients
and controls as regards sRAGE (P< 0.001). Also, there
was a signiﬁcant positive correlation between sRAGE and
SLE-DAI (P< 0.001).
In a study carried by Martens et al.,40 receptor for
advanced glycation end products (RAGE) was associated with
systemic lupus erythematosus disease activity and severity.
Another study carried by Ma et al.,41 the role of high
mobility group box-1 (HMGB1) protein and its receptors in
autoimmune diseases and documented that HMGB1 is associ-
ated with disease activity in patients with SLE. Also, plasma
sRAGE in patients receiving long-period treatment was
signiﬁcantly increased compared to those with short-period
treatment and comparable with those in healthy control.sRAGE.
trol (n= 20) t P
.0–1118.0 6.215* <0.001*
.30 ± 25.01
1.0
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multiligand receptor that propagates cellular dysfunction in
several inﬂammatory disorders. RAGE is expressed at low
levels in normal tissues, but becomes upregulated at sites where
its ligand accumulate. RAGE may play a dual role in the
inﬂammatory responses. sRAGE interaction occurs on leuko-
cytes or endothelial cells with its ligands results in cellular acti-
vation involving the transcription factor NF-kappa B: on the
other hand, sRAGE on endothelial cells may function as an
adhesive receptor that directly interacts with leukocyte SS2-
integrins, thereby directly being involved in inﬂammatory cell
recruitment.
In another study by Millard et al.28 the formation of
advanced glycation end products (AGEs) is a result of the
non-enzymatic reaction between sugars and free amino groups
of proteins. AGEs, through interaction with their speciﬁc
receptor for AGEs (RAGE), result in activation of pro-
inﬂammatory states and involved in numerous pathologic con-
ditions. The soluble form of RAGE is able to act as a decoy to
avoid interaction of RAGE with its pro-inﬂammatory ligands
(AGES, HMGB1, S100 proteins).
The results of the study emphasize the possible involvement
of the sRAGE pathway in the immunopathogenesis of SLE,
which could lead it to have a potential therapeutic role.
6. Recommendations
HMGB1 is a nuclear DNA-binding protein that residues inside
the nucleus detected in renal biopsy of patients with lupus
nephritis. Further studies are promptly needed in order to eval-
uate the importance in determining urinary HMGB-1 and its
value as a biomarker in lupus nephritis patients with renal
involvement.
HMGB1 can be released to the extra-cellular space under
speciﬁc conditions. Whereas HMGB1 is actively released from
lipopolysaccharide (LPS), TNF, IL-1 activated monocytes and
macrophages, its release also occurs passively during late phase
of apoptosis as well as during necrosis.
Urinary biomarkers might be more relevant than serum
biomarkers and could detect both systemic and local inﬂam-
mation, they directly reﬂect renal pathology and possibly, a
therapeutic target.
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